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Background: It is known that miRNAs play various roles in malignant tumors. This study is designed to
investigate whether miR-125b levels can be used to predict the clinical response of patients with os-
teosarcoma (OS) to cisplatin-based chemotherapy.
Methods: From January 2010 to July 2015, 82 patients with resectable OS and 56 patients with un-
resectable OS were enrolled. Blood samples were collected and quantitative real-time PCR was applied to
determine miR-125b expression. Clinical data was collected through medical records, and patients were
treated according to National Comprehensive Cancer Network guidelines on OS.
Results: Our study found that patients with low miR-125b expression had shorter disease-free survival
(po0.001) in the OS group, which was veriﬁed by Kaplan-Meier analysis and univariate and multivariate
Cox analyses (po0.001). For patients with unresectable OS, low miR-125b expression was found to be
associated with advanced tumor stages (p¼0.006). No complete remission was observed, and there were
13 patients with partial remission, 21 with stable disease, and 22 with disease progression. Negative
correlation was found between miR-125b expression and response to chemotherapy (po0.001,
r¼0.606). Furthermore, ROC analysis indicated that miR-125b at the cut point of 0.61 yielded an area
under the ROC curve of 0.793 (po0.001, 95% CI: 0.664–0.890) in distinguishing chemotherapy-resistant
OS from chemotherapy-sensitive OS, with sensitivity and speciﬁcity at 76.9% and 79.1%, respectively.
Kaplan-Meier analysis and univariate and multivariate Cox analyses showed that patients with low miR-
125b expression suffered shorter overall survival (p¼0.014, p¼0.024, and p¼0.049, respectively).
Conclusion: Down-regulation of circulating miR-125b might have the potential to predict cisplatin-based
chemotherapy resistance and poor prognosis in OS.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is the most frequently diagnosed malignant
bone tumor in children and adolescents, and about half of the
cases have lesions localized in the distal femur and proximal tibia
[1]. The incidence of OS is estimated to be about three to ﬁve
cases/million/year, accounting for about 5% of childhood malig-
nancies and about 9% of malignancy-related deaths in children
[2,3]. OS has a high propensity to metastasize, especially to the
lung [4]. The long-term survival rate of OS patients was less than
20% after surgical resection alone prior to the availability of
neoadjuvant and adjuvant chemotherapy in the 1980s [5]. The
5-year survival rate improved to 60–70% after the developmentGmbH. This is an open access art
he Second Clinical Hospital of
lly to this study.
ﬁnancial interests.and use of multi-agent chemotherapy regimens [6]. However, the
improvement of survival has not changed signiﬁcantly for the past
30 years since chemotherapy was developed, and chemoresistance
has become a troublesome obstacle during management of OS.
There is an urgent need to elucidate the molecular mechanisms of
chemotherapy resistance and ﬁnd reliable biomarkers of its de-
velopment. This would greatly help identify more effective biolo-
gical-based therapies and optimize the treatment strategies.
Post-transcriptional regulation by microRNAs (miRNAs) has
been identiﬁed as an important mechanism underlying oncogen-
esis, invasiveness, proliferation, and migration of malignant tu-
mors [7,8]. Growing evidence indicates that various miRNAs (in-
cluding miR-92a, miR-99b, miR-132, miR-193a-5p, miR-422a, and
miR-125b) are involved in the development of resistance to che-
motherapy [5,9,10]. It is thought that miR-125b can act as both an
oncogene and a tumor suppressor, depending on the cellular
context [11–13]. A previous study indicated that miR-125b was
signiﬁcantly reduced in OS tissues, and that it suppresses pro-
liferation and migration of OS cells through down-regulation oficle under the CC BY-NC-ND license
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sensitivity of OS cell lines to cisplatin by targeting Bcl-2 [10].
However, evidence from clinical practice is lacking.
Therefore, this study was designed to explore the possible use
of miR-125b levels in patients to predict the response of OS to
cisplatin-based chemotherapy.2. Patients and methods
2.1. Ethical considerations
The study protocol was approved by the medical ethics com-
mittee of the Second Clinical Hospital of Lanzhou University. In-
formed consent was obtained from all adult participants prior to
the start of the study. For children under 18 years of age, informed
consent was obtained from their legal guardian.
2.2. Patients and samples
Patients with OS who presented to our department between
January 2010 and July 2015 were screened for enrollment. Exclu-
sion criteria were previous malignant tumors in another organ or
system; hematological disorders; end-stage patients not qualiﬁed
for chemotherapy; patients with no pathological data; and any
patients unwilling to participate. Patients were treated according
to National Comprehensive Cancer Network practice guidelines for
OS, and any treatment decisions were not affected by participation
in the study. Patients with resectable OS received cisplatin-based
neoadjuvant and adjuvant chemotherapy and surgery, while cis-
platin-based aggressive chemotherapy was given to OS patients
with unresectable lesions.
The demographic and clinical characteristics of the study par-
ticipants were obtained from their medical records on admission,
and follow-up of patients receiving surgery was performed by the
combination of outpatient visits, letters, and telephone calls. The
patients had follow-up visits with physical examinations and
radiography every 3 months, as well as computed tomography
scans or magnetic resonance imaging when necessary. Disease-
free survival was calculated from the date of surgery until an event
for each patient. For patients with unresectable OS tumors, the
response to chemotherapy was evaluated by the Response Eva-
luation Criteria in Solid Tumors (RECIST). In this study, che-
motherapy sensitivity was deﬁned as complete remission or par-
tial remission, whereas stable disease and disease progression
were taken as signs of chemotherapy resistance [15]. The patients
were also followed for overall survival after therapy, which was
calculated from the date of the beginning of chemotherapy in our
department, until the date of death.
2.3. Sample collection, RNA isolation and quantitative real-time PCR
(qRT-PCR) analysis
In each participant, a 10 mL peripheral venous blood was col-
lected in EDTA anticoagulation tubes before any therapy was be-
gun. The blood samples were centrifuged at 3,000 rpm for 10 min
within 20 min after collection. In order to completely remove the
cellular debris, the supernatant was separated and further pro-
cessed by 15 min of high-speed centrifugation at 12,000 x g. The
ﬁnal plasma was then stored in RNase-free tubes (Axygen, Union,
CA) at 80 °C for further analysis.
Total RNA was extracted from specimens using a mirVana™
PARIS™ kit (Applied Biosystems, USA) according to manufacturer's
protocol. A NanoDrop™ 1000 Spectrophotometer (NanoDrop
Technologies Inc., Wilmington, DE, USA) was used to determine
the concentration of extracted RNAs. Taqmans MicroRNA ReverseTranscription Kits (Applied Biosystems, Foster City, CA, USA) were
then utilized to perform the reverse transcription reactions. A 5 μl
reaction system comprising 0.5 μl of different primers, 0.063 μl of
20 units/μl RNase inhibitor, 0.33 μl of 50 units/μl Multiscribe re-
verse transcriptase, 0.05 μl of 100 mM dNTPs, 0.5 μl of 10 re-
verse transcription buffer, the RNA sample, and RNase-free water
was incubated at 30 °C for 10 min, followed by 30 min of incuba-
tion at 50 °C, at 95 °C for 5 min, and then held at 4 °C.
A Bio-Rad IQ5 (Bio-Rad Laboratories Inc.) thermocycler was
applied for the qPCR reaction. A 10 μl qPCR reaction solution with
5 μl of TaqMan 2 Perfect Master Mix, 2 μl of cDNA solution,
0.25 μl of speciﬁc primers, and 2.75 μl of RNase-free water was
used. U6 snRNA (Ambion, AM30303) was used as a reference miR.
The qPCR primers were miR-125b: sense, 5′-GCUCCCUGA-
GACCCUAAC-3′, and antisense, 5′-CAGTGCAGGGTCCGAGGT-3′; U6:
sense, 5′-CTCGCTTCGGCAGCACATATACT-3′ and antisense, 5′-
ACGCTTCACGAATTTGCGTGTC-3′. The PCR ampliﬁcation was per-
formed as follows: an initial denaturation at 95 °C was carried out
for 2 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for
1 min. The reaction was terminated by incubation at 95 °C for 15 s,
and the products held at 4 °C. The expression level of miR-125b
was calculated using the ΔΔCT method, and each reaction was
repeated in triplicate to avoid bias.
2.4. Statistical analysis
MedCalc for Windows, version 13.0 (MedCalc Software, Ostend,
Belgium) and SPSS version 16.0 (SPSS, Chicago, IL, USA) were used
for statistical analyses. The Kolmogorov-Smirnov test was applied
to test the normality of miR-125b expression in both groups, and
one-way analysis of variance testing, Student's t-test and Spear-
man correlation analysis were ﬂexibly used as appropriate. Re-
ceiver operating characteristic (ROC) curve analysis was conducted
to evaluate the efﬁcacy of miR-125b in distinguishing che-
motherapy resistance in the OS group with unresectable lesions.
The association between miR-125b expression and survival was
assessed by the log-rank test and Cox proportional hazard re-
gression analysis, and age, gender, tumor location, tumor stage,
histologic grade, metastasis status, and miR-125b expression level
were entered into the multivariate analysis. The mean value of
miR-125b expression level was set as the cut-off point to differ-
entiate patients with high or low miR-125b expression in the re-
sectable and unresectable groups. A level of po0.05 was con-
sidered statistically signiﬁcant.3. Results
3.1. Patients’ characteristics
From January 2010 to July 2015, 176 patients who presented
with OS to our orthopedic department were screened. Of these,
138 (78%) were enrolled as participants in the study, 82 with re-
sectable OS and 56 with unresectable OS. The median follow-up
time in the resectable OS group is 23.1710.9 months, while it was
13.976.6 months in the unresectable OS group. The details of
patients’ clinical characteristics are presented in Table 1.
3.2. miR-125b expression proﬁle in the resectable OS group
The miR-125b expression level in the resectable OS group was
normally distributed with a mean of 0.9770.55 (p40.05, Ta-
ble 2), and no signiﬁcant correlation was found between miR-125b
expression and patients’ age, gender, tumor location, tumor grade,
histologic grade, number of metastases, or location (Table 2). The
samples with miR-125b expression less than 0.97 were assigned to
Table 1
Pathological and clinical parameters of the enrolled participants.
Characteristics Resectable OS (n¼82) Unresectable OS (n¼56)
Age (years) 22.879.7 22.979.4
Gender
Male 52 21
Female 30 35
Tumor location
Tibia/femur 58 45
Elsewhere 24 11
Tumor stage
T1 49 17
T2 26 32
T3 7 7
Histologic grade
G1 25 17
G2 26 18
G3 31 21
Number of metastatic sites
0 69 10
1 9 21
Z2 4 25
Metastatic location
Lung 7 18
Other sites 2 6
Lung and other sites 4 22
Previous surgery 9 44
Previous chemotherapy 12 32
Previous radiotherapy 7 15
miR-125b in plasma 0.9770.55 0.5070.25
Note: OS, osteosarcoma.
Table 2
Comparison of miR-125b expression among patients’ characteristics.
Characteristics miR-125b in re-
sectable OS
p miR-125b in un-
resectable OS
p
Age (years) 0.956 0.658
o25 0.9770.51 0.4970.24
Z25 0.9770.62 0.5270.28
Gender 0.094 0.774
Male 0.9070.50 0.4970.25
Female 1.1070.62 0.5170.25
Tumor location 0.635 0.436
Tibia/femur 0.9570.54 0.4870.23
Elsewhere 1.0270.57 0.5570.32
Tumor stage 0.588 0.006
T1 1.0270.54 0.6070.29
T2 0.8870.53 0.5670.25
T3 0.9970.67 0.3470.15
Histologic grade 0.067 0.139
G1 1.0870.59 0.4370.21
G2 0.7770.35 0.5970.23
G3 1.0570.61 0.4770.28
Number of meta-
static sites
0.160 0.789
0 0.9970.55 0.4770.25
1 1.0270.55 0.4870.25
Z2 0.4670.16 0.5270.25
Metastatic location 0.224 0.652
Lung 1.0270.56 0.5070.26
Other sites 1.0370.74 0.4270.19
Lung and other sites 0.4670.16 0.5370.26
RECIST po0.001
Complete response
Partial response 0.6970.24
Stable disease 0.5570.17
Progressive disease 0.3270.21
Note: OS, osteosarcoma; RECIST, Response Evaluation Criteria in Solid Tumors.
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more than the mean value were taken as high miR-125b expres-
sion (n¼54). Kaplan-Meier analysis indicated that patients with
low miR-125b expression suffered shorter disease-free survival
(po0.01, Fig. 1(A)), which was veriﬁed by the univariate and
multivariate Cox proportional hazard regression analysis
(po0.001, Table 3). The multivariate Cox proportional hazard re-
gression analysis also showed that patients with low tumor stage
(T1) experienced longer disease-free survival than those with high
tumor stage (T2þT3) (p¼0.036, Table 3), which was not found by
univariate Cox proportional hazard regression analysis (p¼0.447,
Table 3).
3.3. miR-125b expression proﬁle in the unresectable OS group
The miR-125b expression level in the unresectable OS group
was also normally distributed (p40.05), and averaged 0.5070.25.
No signiﬁcant correlation was found between miR-125b expres-
sion and patients’ age, gender, tumor location, histologic grade,
number of metastasis, or metastatic location (Table 2). Low miR-
125b expression was found to be associated with advanced tumor
stages (p¼0.006). No complete remission was observed, but there
were 13 patients with partial remission, 21 with stable disease,
and 22 with disease progression in the study. There was a sig-
niﬁcant difference of miR-125b expression with different tumor
responses to chemotherapy (po0.001). Spearman correlation
analysis showed a negative correlation between miR-125b ex-
pression and tumor response to chemotherapy (po0.001,
r¼0.606). Furthermore, ROC analysis indicated that miR-125b at
the cut-off point of 0.61 yielded an area under the ROC curve of
0.793 (po0.001, 95% conﬁdence interval (CI): 0.664–0.890) in
distinguishing chemotherapy-resistant OS from chemotherapy-
sensitive OS, the sensitivity and speciﬁcity of which were 76.9%
and 79.1%, respectively (Fig. 2). Kaplan-Meier analysis showed that
the study participants with low miR-125b expression (miR-
125bo0.50) had shorter overall survival (p¼0.014, Fig. 1(B)),
which was consistent with the univariate and multivariate Cox
proportional hazard regression analysis (p¼0.024 and p¼0.049,
respectively, Table 4).4. Discussion
Accumulating knowledge of the molecular pathogenesis of
malignant tumors has provided new insights for disease char-
acterization and therapy; these insights may be applied to selected
patients for more rational treatment decisions and better clinical
outcomes. In recent years, miRNAs, classiﬁed as oncogenes or tu-
mor suppressor genes, have been widely studied and have the
potential to serve as classiﬁcation criteria. In the present study, we
found that OS patients with low miR-125b expression had shorter
disease-free survival in the resectable OS group and shorter overall
survival in the unresectable OS group. Additionally, we found a
negative correlation between miR-125b expression and tumor
response to chemotherapy.
miR-125b is a highly conserved miRNA among different spe-
cies, which includes the miR-99/miR100 and the let7 family
members [16]. It has been reported that miR-125b is involved in
control of cell proliferation, cell cycling, and inﬂammation [17–19].
The role of miR-125b in malignant tumors is controversial: it has
been reported to be overexpressed in prostate cancer and hema-
tological malignances and to act as oncogene [11,13], and is also
reported to be down-regulated in breast, ovarian, and thyroid
carcinomas, as well as hepatocellular cancer, and is assumed to be
a tumor suppressor. [12,18,20]. In OS, miR-125b was down-regu-
lated in human osteosarcoma tissues compared with the adjacent
Fig. 1. Correlation between circulating miR-125b expression and disease-free survival time in the resectable osteosarcoma (OS) group (A) and overall survival time in the
unresectable OS group (B).
Table 3
Cox proportional regression analysis for assessing the correlation of miR-125b
expression in plasma with the disease-free survival of resectable osteosarcoma.
Covariate Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age (years) 0.209 0.243
o25 1.000 1.000
Z25 0.714 0.423–
1.208
0.717 0.410–
1.254
Gender 0.660 0.525
Female 1.000 1.000
Male 0.889 0.528–
1.499
1.206 0.676–
2.152
Tumor location 0.792 0.339
Tibia/femur 1.000 1.000
Elsewhere 1.075 0.628–
1.839
0.746 0.410–
1.359
Tumor stage 0.447 0.036
T1 1.000 1.000
T2þT3 1.223 0.728–
2.054
1.902 1.042–
3.472
Histologic grade 0.449 0.769
G1 1.000 1.000
G2þG3 1.221 0.728–
2.047
1.083 0.635–
1.846
Metastasis 0.484 0.550
No 1.000 1.000
Yes 0.785 0.398–
1.548
0.807 0.400–
1.626
miR-125b
expression
o0.001 o0.001
Low 1.000 1.000
High 0.299 0.171–
0.523
0.230 0.124–
0.426
Fig. 2. Receiver operating characteristic (ROC) analysis to determine the efﬁciency
of circulating miR-125b in separating patients with a poor chemotherapy response.
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associated with advanced TNM stage, metastasis, and higher tu-
mor size, and it was said to be acting as a tumor suppressor [21]. In
the present study, a signiﬁcant correlation was found only be-
tween miR-125b expression and tumor stage in the unresectable
OS group. Various factors may contribute to this difference, such as
race, sample category, sample size, detection techniques, and ex-
perimental reagents. One important factor may be that the prior
study analyzed miR-125b expression in tissue, while we analyzed
miR-125b in plasma. The circulating miR-125b could be easily af-
fected by multiple internal environmental factors.
The key issue in this study is the role of miR-125b in predicting
OS patients’ response to cisplatin-based chemotherapy. For the
resectable OS group, it was hard to evaluate patients’ response tochemotherapy directly. Therefore, we applied disease-free survival
to indirectly assess this, and found that OS patients with low miR-
125b expression suffered shorter disease-free survival. We also
found that patients with low miR-125b expression experienced
shorter overall survival in the unresectable OS group. A previous
study analyzing resected OS tissue found that the overall survival
time was signiﬁcantly shorter in patients with low miR-125b ex-
pression compared with those with high miR-125b expression
[21]. In the present study, RECIST was utilized to assess patients’
response to chemotherapy in the unresectable OS group, and a
negative correlation was found between miR-125b expression and
the tumor response to cisplatin-based chemotherapy. In vitro, si-
milar results were reported previously by Wang et al., who found
that stable overexpression of miR-125b in OS cell lines U2OS and
MG-63 inhibited cell proliferation, migration, and invasion, and
miR-125b increased the sensitivity of OS cell lines to cisplatin [10].
The mechanisms for development of chemotherapy resistance
are complicated, including decreased intracellular drug accumu-
lation, drug inactivation, enhanced DNA repair, perturbations in
signal transduction pathways, apoptosis, cell cycle-related gene
expression turbulence, autophagy-related chemoresistance, and
miRNA dysregulation [1,5]. Furthermore, miRNAs levels have been
shown to be associated with the development of chemoresistance
Table 4
Cox proportional regression analysis for assessing the correlation of miR-125b
expression in plasma with the overall survival of unresectable osteosarcoma.
Covariate Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age(years) 0.708 0.379
o25 1.000 1.000
Z25 0.994 0.965–
1.025
0.698 0.313–1.555
Gender 0.509 0.285
Female 1.000 1.000
Male 1.234 0.661–
2.301
0.693 0.354–1.358
Tumor location 0.755 0.664
Tibia/femur 1.000 1.000
Elsewhere 0.884 0.409–1.912 0.826 0.349–1.958
Tumor stage 0.122 0.374
T1 1.000 1.000
T2þT3 0.608 0.324–1.142 1.443 0.643–
3.239
Histologic grade 0.229 0.198
G1 1.000 1.000
G2þG3 0.672 0.351–1.285 1.558 0.793–
3.058
Metastasis 0.861 0.807
r1 1.000 1.000
Z2 1.055 0.577–1.929 0.921 0.476–1.784
miR-125b expression 0.024 0.049
Low 1.000 1.000
High 0.496 0.269–
0.913
0.485 0.235–
0.998
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193a-5p, miR-422a, miR-140, miR-215, miR-15a, and miR-16–1
have been identiﬁed [9,22–25]. Wang et al. showed that Bcl-2 was
inversely associated with miR-125b in OS tissues, and that miR-
125b could bind to the 3′ untranslated region of Bcl-2 and therapy
reduced its expression [10]. The combined treatment of miR-125b
and cisplatin signiﬁcantly induced cell apoptosis, while over-
expressed Bcl-2 partially reduced the effect induced by miR-125b
plus cisplatin treatment. Additionally, they found that the activity
of caspase 3, a key factor in cell apoptosis, was signiﬁcantly im-
proved with treatment by miR-125b plus cisplatin compared with
miR-125b or cisplatin treatment alone. In contrast, up-regulation
of Bcl-2 attenuated the activation of caspase-3 induced by miR-
125b plus cisplatin treatment. These results showed that miR-125b
improved OS cells’ sensitivity to cisplatin treatment by targeting
Bcl-2 in OS cells [10]. miR-125b could also promote apoptosis by
diminishing the expression of Mcl-1, Bcl-w, and IL-6R [26]. In
contrast, miR-125b could play an anti-apoptotic role through
suppressing Bcl-2 antagonist killer 1 (Bak1) [27]. Moreover, it is
reported that miR-125b could suppress the proliferation and mi-
gration of OS cells through down-regulation of STAT3 [14]. De-
termining the exact mechanism involved in miR-125b regulation
of OS response to cisplatin-based chemotherapy will require fur-
ther investigation.
Although the results of the present study are encouraging,
several limitations need to be acknowledged. First, the sample size
of this study was relatively small, and conﬁrming data from larger
groups of patients are needed. Second, all participants were drawn
from a limited geographic area from a single center, and so whe-
ther the results apply to the whole population is open to question.
Third, previous treatments were excluded from the statistical
analysis. Fourth, the conclusions of the study are derived from the
clinical data; evidence from laboratory studies and the mechanism
by which miR-125b affects OS response to cisplatin-based che-
motherapy are lacking.5. Conclusion
This study presents evidence that miR-125b levels have the
potential to be a valid biomarker to predict the effect of cisplatin-
based chemotherapy and prognosis in OS. The limitation of the
study is that it was derived from a retrospective analysis, and the
positive and negative predictive values of miR-125b testing need
to be evaluated prospectively with predeﬁned cut-off levels and in
a variety of clinical settings and centers before we can be certain of
its efﬁcacy.References
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